Recombinant polyclonal drug trial for HBV gets FDA green light
Drug Discovery World
AUGUST 7, 2024
The US Food and Drug Administration (FDA) has cleared GigaGen’s application to initiate a Phase I trial of its polyclonal drug for the treatment of hepatitis B virus (HBV) infection, GIGA-2339. With over 1,000 different HBV-targeted antibodies in the mixture, GIGA-2339 is unlike any therapy currently in development.
Let's personalize your content